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ABSTRACT 
 The airway epithelium forms a barrier 
between the internal and external environments. 
Epithelial dysfunction is critical in the pathology 
of many respiratory diseases including cystic 
fibrosis (CF). Ets homologous factor (EHF) is a 
key member of the transcription factor (TF) 
network that regulates gene expression in the 
airway epithelium in response to endogenous and 
exogenous stimuli.  EHF, which has altered 
expression in inflammatory states, maps to the 5’ 
end of an intergenic region on Chr11p13 that was 
implicated as a modifier of CF airway disease.  
Here we determine the functions of EHF in 
primary human bronchial epithelial (HBE) cells 
and relevant airway cell lines. Using EHF 
chromatin immunoprecipitation followed by deep 
sequencing (ChIP-seq) and RNA-seq after EHF 
depletion, we show that EHF targets in HBE cells 
are enriched for genes involved in inflammation 
and wound repair. Furthermore, changes in gene 
expression impact cell phenotype, since EHF 
depletion alters epithelial secretion of a neutrophil 
chemokine and slows wound closure in HBE cells. 
EHF activates expression of the SAM pointed 
domain-containing ETS transcription factor 
(SPDEF), which contributes to goblet cell 
hyperplasia. Our data reveal a critical role for EHF 
in regulating epithelial function in lung disease. 
	   	   	   	   	   	   	  
 
 The airway epithelium plays a critical role 
in lung function in both normal and pathological 
states. It forms an active barrier between the 
external and internal environments, responding to 
a wide range of stimuli. Because this cell layer is 
constantly exposed to the outside atmosphere, it 
has developed mechanisms to respond rapidly to 
external insults.  Following mechanical damage, 
the epithelial cells proliferate and migrate to close 
the resulting wound (1). In response to foreign 
pathogens and particles, the cells release immune 
factors (2). The airway epithelium also drives the 
mucociliary escalator, which physically removes 
debris from the lungs (3,4). In the presence of 
chronic damage or infection, these pathways can 
malfunction and contribute to lung pathology in 
diseases such as cystic fibrosis (CF) (3,5,6).  
 CF is a common autosomal recessive 
disorder caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) 
gene.  The main cause of morbidity and mortality 
in CF is lung disease (7).  Airway dysfunction in 
CF patients is complex, but altered ion transport 
leads to a decreased ability to clear 
microorganisms, chronic infection, and 
inflammation.  Neutrophil-dominant inflammation 
is present early in the disease (8). There is 
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increased secretion of cytokines including 
interleukin-13 (IL-13) and interleukin-17a (IL-
17a) in the lungs, which is exacerbated in patients 
infected with Pseudomonas aeruginosa, the 
predominant pathogen in the CF airway (11-13).  
IL-13 augments mucin production by the lung 
epithelium and triggers goblet cell hyperplasia 
(14). IL-17a induces neutrophil chemokine 
production by the epithelial cells (15).  The 
amplified mucus and cytokine levels cause 
destruction of lung tissue by initiating remodeling 
and fibrosis, which correlate with pulmonary 
dysfunction (16-19). Similar pathways are 
activated in other airway diseases, including 
chronic obstructive pulmonary disease (COPD) 
and asthma (20,21).  Modulation of gene 
expression underlies the response of the lung 
epithelium to the environment, both in normal and 
disease states, so it is critical to understand the 
causative mechanisms. Pivotal to these processes 
is the transcription factor (TF) network that 
regulates development, normal function, and 
response to disease in respiratory epithelial cells. 
TFs respond to normal and aberrant stimuli by 
binding to the genome at regulatory sites, thereby 
altering gene expression. Ets homologous factor 
(EHF) is a member of the epithelial-specific Ets 
transcription factor subfamily that is expressed in 
the bronchial epithelium (22-24).  In response to 
inflammatory mediators including interleukin-1β 
(IL-1β) and tumor necrosis factor-α (TNF-α), 
bronchial EHF expression is increased in an NF-
κB-dependent manner, suggesting a role for EHF 
in the epithelial response to inflammation (25). In 
prostate cancer, loss of EHF leads to epithelial-to-
mesenchymal transition (EMT) and increased 
metastatic potential (26).  In EMT, epithelial cells 
lose contact with adjacent cells and become more 
motile (27). Similar pathways may be involved in 
lung fibrosis (28). 
  Recent genome-wide association studies 
(GWAS) led to an interest in EHF as a potentially 
important factor in CF lung pathology. These 
studies identified intergenic single nucleotide 
polymorphisms (SNPs) at chr11p13 that strongly 
associate with lung disease severity in CF patients 
carrying the most common disease-causing 
mutation, F508del (29,30). These SNPs are likely 
within or close to cis-regulatory elements for 
nearby genes. EHF maps immediately adjacent 
(5’) to this intergenic region, suggesting a role as a 
modifier of lung disease in CF patients. We 
hypothesize that EHF regulates genes involved in 
cellular processes that impact the severity of 
epithelial pathology in airway disease, including 
inflammation and wound repair. 
 This study investigates the role of EHF in 
primary human bronchial epithelial (HBE) cells. 
Using chromatin immunoprecipitation followed by 
sequencing (ChIP-seq) and RNA-sequencing 
(RNA-seq) after EHF depletion, we identified 
putative direct targets of EHF in HBE cells.  These 
genes are enriched in processes that are involved 
in lung pathology. Cellular assays determined that 
EHF-modulated changes in gene expression alter 
epithelial phenotypes. Our results suggest that 
EHF is involved in multiple processes that 
influence lung function in disease. Of particular 
relevance to CF are the release of neutrophil 
chemokines and wound repair.  
 
RESULTS 
 ChIP-seq generates a genome-wide 
binding signature for EHF in primary HBE cells− 
To identify genome-wide binding sites for EHF, 
ChIP-seq was performed on cultures from two 
tissue donors.  The antibody specific for EHF was 
used previously for ChIP-seq in Calu-3 lung 
adenocarcinoma cells (31). The HOMER 
irreproducible discovery rate pipeline (32) was 
used to call a total of 11,326 peaks with an 
irreproducible discovery rate (IDR) < 0.05 (Table 
S1). Sonicated input DNA was used as 
background. The normalized tag counts at each 
called peak were significantly correlated between 
the two biological replicates (r=0.29, p<0.0001).  
 The Cis-regulatory Element Annotation 
System (CEAS) software (33) was used to 
annotate peaks based on genomic location (Fig 
1A) and determined that EHF sites were enriched 
at promoters (-1 kb relative to the transcription 
start site) and 5’ untranslated regions (UTRs) of 
genes (Fig 1B). Consistent with its role as a TF 
controlling cell-type specific gene expression, 
peaks of EHF occupancy were also found in 
intergenic and intronic regions, which may 
represent cis-regulatory elements such as 
enhancers.  These regulatory sites are marked by 
specific histone modifications. Active or poised 
promoters and enhancers are enriched for histone 
3 lysine 4 trimethylation (H3K4me3) and 
H3K4me1, respectively, while active regions are 
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specifically marked by histone 3 lysine 27 
acetylation (H3K27ac) (34,35). To determine 
whether EHF peaks are found in regions with 
these histone modifications, as predicted by their 
genomic locations, ChIP-seq was performed using 
antibodies against H3K4me1, H3K4me3 and 
H3K27ac in HBE cells.  EHF sites were enriched 
for all marks with a bimodal distribution around 
the center of the peak, in accordance with a 
nucleosome depleted center region where 
transcription factors bind (Fig 1C). Consistent 
with an over-representation of EHF sites at 
promoters, the H3K4me3 mark was the most 
enriched.  
 De novo motif analysis was performed on 
the significant EHF ChIP-seq peaks, which 
identified the epithelial-specific Ets motif as the 
most enriched, found in 84.25% of sites within 
200bp of the center of the peak (Fig 2A). The 
motif analysis also identified secondary enriched 
motifs. The binding motifs for activator protein-1 
(AP-1), Forkhead domain and Krüppel-like factor 
(KLF) transcription factor families were among 
the most enriched secondary motifs, found in 
20.94%, 15%, and 13.54% of peaks, respectively 
(Fig 2A).  
 To confirm that EHF and AP-1 co-localize 
in the genome, ChIP-seq for c-Jun and JunD, 
members of the AP-1 protein complex, was 
performed in Calu-3 lung adenocarcinoma cells. 
ENCODE consortium-validated antibodies were 
used to perform 2 biological replicates for each 
protein, and the HOMER IDR method was used to 
call significant peaks of transcription factor 
binding. A total of 11,517 and 7,524 sites were 
identified for c-Jun and JunD, respectively. In 
addition, the HOMER IDR protocol was used to 
call peaks in 2 biological replicates of EHF ChIP 
performed in Calu-3 cells, which we published 
previously (31). These three data sets were then 
intersected (Fig 2B). Twenty-five percent of the 
EHF peaks overlapped at least one c-Jun or JunD 
peak, with 59% of these containing both c-Jun and 
JunD sites, 32% having only c-Jun and 9% 
containing only JunD. EHF sites that overlap JunD 
binding sites are enriched at the promoters (Fig 
2C). The nearest gene annotation method was used 
to determine potential genes regulated by the 
overlapping binding sites, and these were 
subjected to a gene ontology process enrichment 
analysis using MetaCore from Thomson Reuters 
version 6.26 (Fig 2D).  The overlapping sites are 
found near loci involved in differentiation, 
development and wound repair, suggesting they 
may have a combined role in regulating 
phenotypes important for lung pathology.   
 EHF regulates genes involved in lung 
pathology −To detect genes that are directly and 
indirectly regulated by EHF, RNA-seq was 
performed on EHF-depleted (using a targeted 
siRNA) and negative control siRNA-treated HBE 
cells (Fig 3A). Cufflinks (36) was used to identify 
a total of 1,145 genes that were differentially 
regulated (DEGs) following EHF depletion (FDR 
<0.05), with 625 increasing and 520 decreasing in 
expression (Fig 3B, Table S2).  A multi-
dimensional scaling (MDS) analysis was 
performed, which confirmed that 4 of 5 samples 
within each treatment clustered together and away 
from the second group (Fig S1). 
 To identify putative direct targets of EHF, 
the EHF ChIP-seq data and the DEGs identified by 
RNA-seq after EHF depletion were intersected 
using Binding and Expression Target Analysis 
(BETA) (37). EHF was found to have significant 
activating and repressive function (Fig 3C), 
consistent with gene expression changes in the 
positive and negative direction following EHF 
knockdown. This analysis revealed 425 putative 
direct targets that are repressed by EHF, and 434 
that are activated (Tables S3 and S4). The 
forkhead box A1 (FOXA1) motif was enriched in 
EHF sites near repressed genes as compared with 
non-regulated genes (p=2.85e-13). The EHF-
repressed genes included the following that encode 
transcription factors: GATA binding protein 6 
(GATA6), v-myc avian myelocytomatosis viral 
oncogene homolog (MYC), CCAAT/enhancer 
binding protein (C/EBP) gamma and beta (CEBPG 
and CEBPB), HOP homeobox (HOPX), and 
KLF5. Genes activated by EHF include the SAM 
pointed domain-containing ETS transcription 
factor (SPDEF), which is involved in airway 
goblet cell development (38,39), and the 
inflammatory S100 calcium binding proteins 
S100A8, S100A9, and S100A12. 
 An enrichment analysis was performed on 
up-regulated and down-regulated predicted direct 
targets using MetaCore (Fig 3D).  EHF-activated 
genes were found in pathways including regulation 
of degradation of misfolded proteins, extracellular 
matrix (ECM) remodeling, and EMT; diseases 
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comprising infections and inflammation; and gene 
ontology processes including response to stress, 
immune response, and response to wounding.  
EHF-repressed genes were enriched in gene 
ontologies involving negative regulation of RNA 
synthesis, transcription and metabolic processes.   
 EHF and FOXA1 may co-regulate 
transcription factors important for lung epithelial 
development−Lung organogenesis and airway 
epithelial differentiation are complex processes 
coordinated by a network of transcription factors. 
Multiple TFs within this network were identified 
as putative EHF targets in our genome-wide data. 
These include genes with nearby peaks of EHF 
occupancy and/or DEGs after EHF depletion, 
among which are GATA6, HOPX, KLF5, SPDEF, 
retinoic acid receptor beta (RARB), FOXA1 and 
FOXA2. To validate direct or indirect targets, EHF 
was depleted in primary HBE cell cultures derived 
from 4 HBE donors (Fig S2).  Expression of key 
TFs was determined using reverse transcription 
and quantitative polymerase chain reaction (RT-
qPCR) (Fig 4A). HOPX, KLF5, and RARB 
abundance significantly increased following EHF 
depletion, SPDEF levels significantly decreased. 
CEBPG and FOXA1 showed an increase and 
decrease, respectively, that did not reach statistical 
significance (CEBPG p=0.056, FOXA1 p=0.08). 
Because of the substantial variation between 
primary cultures, these non-significant changes 
may be biologically relevant, but would require 
additional validation. GATA6 showed no change, 
and FOXA2 levels were variable between donors. 
Nearby peaks of EHF occupancy evident in the 
ChIP-seq data suggest that most of these genes 
may be direct targets (Fig 4C, S3). To confirm this 
prediction, 4 biological (donor) replicates of EHF 
ChIP-qPCR were performed in primary HBE 
cultures (Fig 4B).  EHF binding was confirmed at 
intron 1 of CEBPG, intergenic sites 5’ of FOXA1, 
HOPX, and RARB, and the promoter of SPDEF.  
 The sites of EHF occupancy near CEBPG, 
HOPX, RARB, and SPDEF also contain sequences 
with the Forkhead domain motif. Since EHF 
represses all but one of these genes (SPDEF), and 
the FOXA1 motif is enriched amongst EHF 
binding sites near repressed genes genome-wide, 
we next asked whether FOXA1 co-regulates gene 
expression with EHF at these loci. FOXA1 was 
depleted in HBE primary cultures from 3 donors 
using a specific siRNA and a non-targeting 
control, and gene expression was measured by RT-
qPCR (Fig S4, 4D). Depletion of FOXA1 
significantly elevated expression of EHF, FOXA2, 
HOPX and KLF5, and decreased SPDEF levels 
(p=.008). RARB did not change. Furthermore, the 
EHF sites near HOPX and SPDEF were bound by 
FOXA1 as shown by 4 biological replicates of 
ChIP-qPCR in primary HBE cells from 2 donors 
(Fig 4E). The FOXA1 enrichment near RARB was 
lower than the other sites, which may explain why 
FOXA1 KD does not alter RARB expression. 
 EHF depletion alters expression of 
cytokines important for neutrophil migration and 
survival−Genes involved in inflammation and 
infection are enriched among putative direct 
targets of EHF identified by ChIP-seq and RNA-
seq. Two EHF binding sites were observed at the 
chr4q13.3 region encompassing the genes for the 
neutrophil chemokines CXCL1, CXCL6, and IL8, 
one 5’ to IL8 and the other 3’ to CXCL1 (Fig 5A). 
The sites identified by EHF ChIP-seq were 
confirmed by ChIP-qPCR in HBE cell chromatin 
from 4 donors (Fig 5A). The bronchial epithelium 
releases these cytokines in response to stimuli 
including IL-17a, a pro-inflammatory cytokine 
involved in multiple lung pathologies including 
CF (12,15), and lipopolysaccharide (LPS), a 
component of the gram-negative cell wall that 
induces a strong immune response in the lung 
(40). The role of EHF in regulating these immune 
mediators was studied in Calu-3 lung 
adenocarcinoma cells, which express CXCL1, 
CXCL6 and IL8. To determine whether EHF 
regulates secretion of the three cytokines encoded 
by these genes, both at a basal level and in an 
inflammatory milieu, EHF was depleted in Calu-3 
cells using a specific siRNA, with a non-targeting 
siRNA as control (Fig S5, S6). Cells were then 
treated with vehicle (bovine serum albumin 
[BSA]) or IL-17a for 4 hours, or vehicle (PBS) or 
LPS from Pseudomonas aeruginosa for 24 hours, 
and RNA was extracted. Cytokine expression was 
then quantified using RT-qPCR (Fig 5B-C). 
CXCL6 expression was repressed upon EHF 
depletion in normal conditions and following LPS 
and IL-17a treatment. EHF knockdown was 
associated with increased IL8 expression 
following LPS treatment, but there was no change 
in basal levels. CXCL1 was not significantly 
regulated by EHF in either condition. To 
determine if the changes in CXCL6 transcript 
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abundance altered CXCL6 cytokine secretion, 
colorimetric sandwich ELISAs were utilized to 
quantify its release into conditioned media.  EHF 
depletion decreased CXCL6 secretion (Fig 5D), 
but did not significantly alter IL-8 secretion (Fig 
5E), consistent with no change in IL8 expression 
at basal levels. 
 Depletion of EHF slows wound closure in 
HBE cells from wildtype and cystic fibrosis 
patients−Among genes with nearby peaks of EHF 
occupancy that are also activated by EHF are 
many that are involved in EMT and response to 
wounding. When the lung epithelial barrier is 
damaged, cells at the edge of the wound migrate to 
close it.  This mechanism may be impaired in 
airway epithelial cells that carry a CFTR mutation, 
suggesting that it contributes to CF lung pathology 
(5,41). Wound repair can be measured in vitro 
with a wound scratch assay, which was performed 
in primary HBE cells from 3 wildtype (WT) and 3 
CF donors. EHF was depleted using siRNA, and 
the cells were grown to a confluent layer on plastic 
(undifferentiated).  The layer was scratched, and 
the wounds were imaged at 0, 3 and 6 hours post-
injury (Fig 6A). By 6 hours, many of the scratches 
had closed. The cells were lysed and EHF 
depletion was confirmed by quantification of 
western blots by gel densitometry (Fig 6B-C). The 
initial wound size was not significantly different 
between the negative control (NC) and EHF 
siRNA treated cells. The area was measured at 
subsequent time points and the percent of initial 
injury size was calculated (Fig 6D-E). In WT HBE 
cells at the 3 hour time point, the scratches in the 
EHF depleted cells remained significantly larger 
than those in the NC cells (p<0.01). In CF cells, 
EHF knockdown significantly delayed the 
reduction in wound size at both 3 and 6 hours. 
This corresponds to a slowing of wound closure in 
the EHF depleted cells compared to NC in both 
WT and CF cells. 
 
DISCUSSION 
 Our data show that EHF is a critical 
regulator of multiple lung epithelial functions that 
are integral to pulmonary diseases, including 
cystic fibrosis. Among CF patients there is a wide 
variation in airway phenotypes, which are under 
strong genetic control (42). However, lung disease 
severity does not correlate with specific mutations 
in CFTR (43), implicating other loci (gene 
modifiers) in modulating lung disease in this 
population. Our data suggest EHF may be one of 
those modifiers based on its functions described 
here and its genomic location at chr11p13, 
adjacent to SNPs that strongly associate with lung 
disease severity in CF patients (29,30). Previous 
genome-wide studies of EHF demonstrated its 
contribution to maintenance of epithelial barrier 
integrity and wound repair in Calu-3 lung 
adenocarcinoma cells (31) and in the mouse 
cornea (44).  Here, we investigated the role of 
EHF in primary HBE cells, with a focus on 
understanding how it may contribute to lung 
pathology.  The outcomes not only confirm our 
previous observations, but also reveal substantial 
novel findings on how EHF participates in lung 
epithelial differentiation and inflammation. 
 The intersection of ChIP-seq data sets 
gives an overall indication of the function of EHF 
with respect to gene regulation.  EHF sites are 
over-represented at promoters (1 kb upstream of 
the TSS). A role for EHF in both activating and 
repressing gene expression is confirmed by the 
BETA output, which shows significant activity in 
both directions. This is consistent with previous 
studies at specific loci that demonstrate both active 
and repressive actions for EHF, depending on the 
cellular context (22,47,48). In our current data, the 
fraction of genes activated by EHF is greater than 
the repressed component, consistent with the 
presence of active histone marks at EHF sites. 
 Since EHF occupies the relatively 
common Ets motif, and it can increase or decrease 
gene expression, its interactions with other TFs are 
likely critical to specify binding location and 
mechanisms of action.  The motif analysis of EHF 
binding sites in HBE cells shows that the most 
enriched secondary motif is for AP-1.  These data 
are consistent with our previous findings that the 
AP-1 motif is over-represented in sites of EHF 
occupancy in Calu-3 cells (31). The AP-1 TF 
complex is made up of hetero- and homo-dimers 
of Jun, Fos and other family members. Regulation 
of transcription by AP-1 has an important role in 
differentiation, cell injury, inflammation and 
apoptosis in the lung (49,50). AP-1 activation may 
be elevated in CF tracheal cells as compared to 
their wildtype counterparts (51). EHF represses 
genes that contain both EHF and AP-1 motifs at 
their promoters (22), which suggests that the two 
factors can co-regulate gene expression. To 
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determine whether EHF and Jun proteins co-
localize genome-wide, we performed ChIP-seq for 
c-Jun and JunD in Calu-3 cells and intersected 
these data with our EHF occupancy profile 
published previously (31). There is significant 
coincidence between binding sites for EHF and 
both AP-1 complex proteins. The overlapping sites 
are found near genes involved in multiple 
pathways important for lung epithelial function in 
disease, including differentiation and wound 
repair. Further investigation of genes co-regulated 
by EHF and AP-1 could elucidate potential targets 
to modulate inflammation and wound repair in the 
airway. 
 Normal homeostasis in the lung 
epithelium depends on appropriate responses to 
external stimuli.  An abnormal or exaggerated 
reaction can initiate or exacerbate lung disease.  
The pivotal role of several TFs in airway 
development and differentiation is well 
documented, particularly through studies in 
rodents. Nkx2-1 is the first marker of anterior 
foregut cells that will become respiratory epithelial 
progenitors (52). FoxA1 and FoxA2 are pioneer 
transcription factors required for branching 
morphogenesis early in lung development and 
epithelial differentiation at later stages (53,54). 
Retinoic acid receptor (RAR) signaling is also 
necessary for proper branching morphogenesis 
(55). GATA6 is involved in lung epithelial 
differentiation throughout development, but is also 
active in post-natal epithelial regeneration (56-58). 
Hopx acts downstream of Nkx2-1 to repress 
expression of GATA6/Nkx2-1-induced expression 
of type II pneumocyte genes, and is critical for 
alveolar development (59), while Klf5 is required 
for maturation of the alveolar respiratory 
epithelium (60).  SPDEF is involved in airway 
goblet cell differentiation and mucus production 
and antagonizes the action of FoxA2 (61).  While 
these TFs are best studied in airway epithelial 
development, they are also likely to be involved in 
epithelial regeneration and dysplasia during 
disease. Here, we demonstrate that EHF 
contributes to the transcriptional network 
controlling pulmonary gene expression.  
 By integrating the results of EHF ChIP-
seq and its depletion followed by RNA-seq, we 
identified putative direct targets of the protein.  
TFs involved in lung development are among 
these identified targets.  EHF represses HOPX, 
KLF5, and RARB, likely through binding to the 
promoter or a nearby cis-regulatory element. EHF 
binding sites are enriched for the Forkhead motif, 
which is bound by both FOXA1 and FOXA2. 
Interestingly, FOXA1 and EHF regulate each 
other and impact expression of downstream TF 
targets similarly. Hence, these two factors may 
cooperate, and perhaps participate together in a 
feedback loop. 
 Although it represses most TFs involved 
in lung development, EHF enhances the 
expression of SPDEF, which participates in goblet 
cell differentiation in the airway, and is induced by 
IL-13 (38,39).  Given the known role of SPDEF in 
goblet cells (38,39,62), these data implicate EHF 
in activating goblet cell differentiation, and 
perhaps perturbing that of other lineages. This 
suggests that EHF contributes to an IL-13-
mediated cell differentiation pathway by activating 
SPDEF and repressing other transcription factors. 
IL-13 is a Th2 cytokine that induces goblet cell 
hyperplasia in the airway through SPDEF, with 
known roles in CF, asthma, and COPD 
(11,13,38,39). Previously, immunohistochemical 
analysis showed the most intense staining for EHF 
in the airway was in mucous gland epithelial cells, 
with a smaller fraction of bronchial epithelial cells 
being positive for EHF (22,23). The pivotal role of 
submucosal glands in CF airway pathology (63) is 
particularly relevant to these observations. 
 In airway diseases such as CF, both IL-13 
and IL-17a play a prominent role in promoting 
inflammation.  Having observed that EHF 
influences expression of genes downstream of IL-
13, we chose also to investigate a potential 
function downstream of IL-17a. Il-17a induces 
bronchial epithelial cells to release neutrophil 
chemokines, including CXCL1, CXCL6 and IL-8 
(15).  These cytokines promote migration and 
survival of neutrophils. This is critical for CF lung 
disease, as a neutrophil-dominant inflammation is 
present early in the illness (8-10). Release of 
proteases by neutrophils contributes to lung 
damage (64,65).  EHF depletion in lung 
adenocarcinoma cells increases IL8 expression and 
decreases CXCL6 expression, This correlates with 
changes in secretion of CXCL6. By increasing 
CXCL6 secretion, EHF could increase neutrophil 
recruitment and survival, thereby exacerbating 
inflammation in the CF lung. 
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 Another important function of lung 
epithelial cells that may be impaired in CF is 
response to wounding (5,41). This is problematic 
in a disease characterized by inflammation and 
resulting damage to the lung epithelium. We 
previously showed that EHF depletion slows 
scratch wound closure in Calu-3 lung 
adenocarcinoma cells (31). Consistent with these 
earlier observations are the current genome-wide 
studies in HBE cells, which show an enrichment 
of EHF-activated genes in EMT and response to 
wounding.  Moreover, we demonstrate here that 
EHF depletion slows wound scratch closure in 
both WT and CF HBE cells. By further impairing 
a phenotype that may already compromised in 
CFTR mutant epithelial cells, EHF could modify 
lung disease severity in CF patients. There are 
certain limitations to the scratch assays performed 
here because the cells are not differentiated on 
permeable supports.  Hence, some epithelial cells 
types are absent and cannot contribute to normal 
wound closure. Differences in the transcriptome of 
differentiated and undifferentiated cells may also 
alter their interactions with the environment. 
 Overall, this study makes a strong case for 
EHF as a potential modifier of lung pathology in 
cystic fibrosis and other diseases in which the 
immune system and epithelial repair mechanisms 
play a critical role, including COPD and asthma. 
Although we have not yet established a correlation 
between the SNPs associated with lung disease 
severity in CF and EHF transcription, we predict 
based on our EHF functional data in HBE cells 
that regulatory variants may impact its expression.  
A detailed investigation of control mechanisms for 
EHF is required to reveal their contribution to 
airway disease. 
 
EXPERIMENTAL PROCEDURES 
 Cell culture−Calu-3 cells were obtained 
from ATCC and cultured by standard methods. 
Passage 1 (P1) primary bronchial epithelial cells 
were obtained under protocol #03–1396 approved 
by the University of North Carolina at Chapel Hill 
Biomedical Institutional Review Board. Informed 
consent was obtained from authorized 
representatives of all organ donors.  Cells were 
grown on collagen-coated plastic in bronchial 
epithelial growth medium (BEGM) (66). Passage 
2 or 3 primary cells were used for the study.  
 
 ChIP-seq and ChIP-qPCR−Antibodies 
used in ChIP-seq were against EHF (Clone 5A.5) 
(22), H3K4me1 (ab8895, Abcam (Ab)), H3K4me3 
(07-0473, Millipore), H3K27ac (ab4729), c-Jun 
(sc-1694, Santa Cruz (SC)), and JunD (sc-74). 
ChIP-seq was performed as described previously 
(31) (ChIP-seq experiment information is shown 
in Table S5). For EHF ChIP-seq, replicates were 
performed on HBE cells from 2 donors. One donor 
was used for histone modification ChIP-seq. For c-
Jun and JunD ChIP-seq, two biological replicates 
were performed on Calu-3 cells. Peaks were called 
using the HOMER-IDR method (IDR<0.05) (32). 
Histone tag directories were generated using 
HOMER (68). Downstream analysis was 
performed using HOMER and Cis-regulatory 
Element Annotation System (CEAS) (33). To 
confirm EHF results, ChIP was performed as 
described followed by qPCR using primer pairs 
specific for each target of interest and SYBR green 
(Life Technologies, LT). FoxA1 ChIP was 
performed as described previously (69) with 
antibody against FoxA1 (ab23738). For primers 
see Table S6. All data are deposited at GEO (GSE: 
GSE85403). 
 RNA-seq−HBE cells were treated with 
30nM of either Silencer Select negative control 
siRNA #2 (4390846) or EHF siRNA (s25399, both 
from Ambion) using RNAiMax transfection 
reagent (LT). 48 hours after transfection, RNA 
was isolated from 5 samples of each treatment 
using TRIzol (LT).  RNA-seq was performed as 
described previously (31) (see Table S7 for 
replicate information). Differentially expressed 
genes were identified using TopHat and Cufflinks 
(36).  Direct targets of EHF were identified using 
Binding and Expression Target Analysis (BETA) 
(37). This software assigns transcription factor 
binding peaks to genes using a model that 
decreases the regulatory potential of the TF 
binding site as the distance to the TSS increases, 
then sums the contribution of multiple sites near a 
gene (in this analysis, within 10 kb or a CTCF site, 
whichever is closer). It also takes into account the 
significance of gene expression changes following 
modulation of the transcription factor (with an 
FDR <0.1).  All data are deposited at GEO (GSE: 
GSE85403). 
 EHF and FoxA1 knockdown followed by 
RT-qPCR−TF depletion was done in 3 (FoxA1) or 
4 (EHF) HBE donor cultures. EHF depletion was 
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as described above. For FOXA1, HBE cells were 
treated with 20nM of control siRNA-A (sc-37007, 
SC) or HNF-3α siRNA (sc-37930, SC) using 
RNAiMax. RNA was isolated 48 (FOXA1) or 72 
(EHF) hours as above.  RT-qPCR was performed 
using TaqMan Reverse Transcription Reagents kit 
(LT), primer pairs specific to each gene and SYBR 
green (for primers see Table S6). 
 Western Blot−HBE and Calu-3 cells were 
lysed in NET buffer and proteins analyzed by 
standard methods. Antibodies used were specific 
for EHF (Clone 5A.5), β-tubulin (T4026, Sigma-
Aldrich), GAPDH (Cell Signaling).  
 LPS and IL-17a treatment of Calu-3 
cells−Cells were forward transfected with NC or 
EHF siRNA as above. Forty-eight hours later, 
cells were serum starved for 24 hours, then treated 
with PBS or 1µg/mL Pseudomonas aeruginosa 
LPS (Sigma, L9134) for 4 hours; or BSA or 
10ng/mL IL-17a (R&D Systems) for 24 hours.  
RNA was isolated using TRIzol, and RT-qPCR 
(SYBR green) was performed as above (For 
primers see Table S6). 
 ELISAs−Cells were forward transfected 
with NC or EHF siRNA as described. 48 hours 
post-transfection, media was replaced with serum-
free media and conditioned for 24 hours. Media 
was removed and diluted. Quantikine colorimetric 
sandwich ELISA for IL-8 (D800C) and CXCL6 
(DGC00, both from R&D) was performed 
according to the manufacturer’s protocol.   
 Wound repair assay−Wound closure 
assay was performed as previously described (31) 
on 3 donor wildtype HBE cultures and 3 donor CF 
HBE cultures. Images were obtained at room 
temperature using a Leica DMi1 microscope with 
a PH1 10x objective using an Olympus DP22 
camera and cellSens Entry software.  
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Fig 1. EHF ChIP-seq sites are over-represented at promoters and enriched for activate
histone marks. EHF ChIP-seq was performed in undifferentiated HBE cells from 2 donor
cultures. A) Percentage of EHF binding sites found at promoters (1 kb upstream of transcription
start sites [TSS]), downstream of genes (1 kb), 5’ untranslated regions (UTRs), 3’ UTRs, exons,
introns, and intergenic sites. B) Percentage of EHF ChIP-seq peaks found at specific sites
compared to genomic background. Bidirectional promoters (Bidir. prom.) are considered 2.5 kb
upstream of TSSs. P-values, derived using CEAS (one-sided binomial test), are shown. C)
Normalized tag counts from H3K4me1, H3K4me3, and H3K27ac ChIP-seq in undifferentiated
HBE cells, as measured from the center of i) all EHF, ii) promoter-, iii) intronic- and iv)
intergenic- binding sites. Tag counts for input sonicated HBE DNA provide a control.
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Figure 2. EHF and the activator protein 1 (AP -1) transcription factor complex bind at 
overlapping sites genome-wide. A) De novo motif analysis within 200 bp of the center of EHF 
ChIP-seq peaks in undifferentiated HBE cells identified enriched motifs. P-values, derived by 
HOMER using cumulative binomial distributions, and percent of EHF sites and of background 
containing each motif are shown below the sequence. B) Intersection of EHF, c-Jun and JunD 
ChIP-seq binding sites in Calu-3 cells. C) Annotation of EHF/c-Jun, EHF/JunD, and EHF/c-
Jun/JunD overlapping sites, compared to the percentage of the genome. P-values derived using 
CEAS (one-sided binomial test). D) Gene ontology process enrichment analysis was performed 
on the nearest gene to each EHF/c-Jun, EHF/JunD, and EHF/c-Jun/JunD intersecting region. 
Shown are the negative logs of the P-values, derived using MetaCore. Abbreviations: Resp. = 
response, comp. = compound, rec. = receptor, sig. = signaling, reg. = regulation, also used in 
Figure 3D. 
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Figure 3. EHF depletion followed by RNA -seq identifies targets involved in the immune 
response and gene regulation. A) siRNA depletion of EHF in undifferentiated HBE cells was 
measured by western blot with -tubulin as a loading control.  B) Relative expression of 1,145 
genes that show a significant change in expression following EHF depletion in undifferentiated 
HBE cells (FDR < 0.05). Each row signifies a different gene. The scale is log2 fold change 
relative to average gene expression. C) Activating and repressive function prediction of EHF in 
undifferentiated primary HBE cells as determined by BETA software. The red, purple, and 
dashed lines indicate the down-regulated, up-regulated, and non-differentially expressed genes, 
respectively. P-values of activated and repressed genes compared to non-regulated genes were 
determined by a Kolmogorov-Smirnov test. D) MetaCore enrichment analysis of direct targets of 
EHF. Analysis was performed on EHF-activated (black) and –repressed (grey) genes, and divided 
into gene ontology processes (top), pathways (middle) and diseases (bottom). Shown are the 
negative logs of the P-values, derived using MetaCore. Abbreviations: Neg. = negative, NA = 
nucleic acid, pos. = positive, dep. = dependent. 
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Figure 4. EHF and FOXA1 regulate other transcription factors involved in airway epithelial
differentiation in HBE cells. A) EHF depletion by siRNA followed by RT-qPCR identified
changes in TF gene expression (n=4). B) EHF ChIP-qPCR confirmed binding at specific sites
identified in EHF ChIP-seq (n=4). C) In each panel, Genome Browser tracks show EHF peaks
identified by IDR in HBE cells at the top (black), below are the EHF ChIP-seq tag counts (teal)
and the gene (blue) for i) CEPBG, ii) FOXA1, iii) HOPX, iv) RARB, and v) SPDEF. D)
Alterations in EHF levels and EHF-regulated TF gene expression after FOXA1 siRNA
knockdown, shown by RT-qPCR (n=3). E) FOXA1 ChIP-qPCR confirmed its binding to a subset
of EHF sites (n=4). Experiments shown in panels A-E were performed in undifferentiated HBE
cells. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by an unpaired two-tailed Student’s t test.
Also used in Figure 6. Bars show average of all experiments, with error bars representing
standard deviation (SD).
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Figure 5. EHF depletion in Calu-3 cells alters secretion of a neutrophil chemokine. A) EHF 
ChIP-qPCR confirmed its binding to sites near IL8, CXCL6, and CXCL1 in HBE cells. Average 
of all experiments with SD (n=4) (top). Graphic of the chr4q13.3 region with EHF ChIP-seq
peaks (bottom). B-C) EHF was depleted (siRNA) in Calu-3 cells followed by their exposure to 
carrier, IL-17a (B), or LPS (C). Gene expression was measured by RT-qPCR. -actin (ACTB) 
was included as a negative control. **P<0.01 by a 2-way ANOVA plus multiple comparisons test. 
Average with SD. D-E) Secretion of CXCL6 (D) and IL-8 (E) into media conditioned 
by NC- and EHF-depleted Calu-3 quantified by colorimetric sandwich ELISA (n=3). *P<0.05 by 
a paired two-tailed Student’s t test. Bars show average of all experiments, with error bars 
representing SD.  
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Figure 6. EHF depletion slows wound closure in wildtype (WT) and cystic fibrosis (CF) HBE 
cells.  A) Images of NC and EHF siRNA-treated WT and CF undifferentiated HBE cells at 0, 3, 
and 6 hours after initial wounding. Outlines of wounds are traced in white. B-C) siRNA depletion 
of EHF was confirmed by western blot and quantified using gel densitometry in B) WT and C) 
CF cells (average with SD). D-E) Percent of initial wound size was measured at all time points. 
Average with SD for D) WT and E) CF HBE cells (3 donor cultures).  
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